Form 4: KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting of restricted stock units and performance stock units.

Summary

• Christopher Yea, the Chief Development Officer of KalVista Pharmaceuticals, executed transactions involving the company's common stock.
• On May 17, 2024, Mr. Yea converted 18,789 restricted stock units (RSUs) and performance stock units (PSUs) into common stock.
• On May 20, 2024, Mr. Yea sold 11,610 shares of common stock at a weighted average price of $11.7645 per share, with prices ranging from $11.7644 to $11.95.
• The sale was to cover tax withholding obligations associated with the vesting of the RSUs and PSUs and was not a discretionary transaction.
• Following these transactions, Mr. Yea directly owns 80,074 shares of KalVista Pharmaceuticals common stock and holds 14,190 RSUs, 14,583 RSUs, 0 PSUs, and 14,583 PSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects, although sales to cover tax obligations are generally considered non-discretionary.

Comparison to Industry Standards

• Executive compensation packages often include stock options, restricted stock units (RSUs), and performance stock units (PSUs) as incentives.
• The vesting schedules described are typical, with quarterly vesting over a period of years.
• Sales of shares to cover tax obligations are a standard practice among executives receiving equity compensation.
• Comparable companies in the pharmaceutical industry, such as BioCryst Pharmaceuticals and Ionis Pharmaceuticals, also see regular Form 4 filings related to executive stock transactions.

Key Dates